Avrobio stock rises as gene therapy for Gaucher disease gets ILAP designation in UK
seekingalpha.com
business
2022-10-18 12:06:44

Artur Plawgo The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to Avrobio's (NASDAQ:AVRO) gene therapy AVR-RD-02 to treat Gaucher disease. The Innovation Passport is the first step in the ILAP process for regulatory and development milestones with the aim of early patient access in the U.K., the company said in a statement on Tuesday. Avrobio's noted that AVR-RD-02 has previously received fast track status in the U.
